Cargando…
Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases
BACKGROUND: We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first‐line treatment for brain metastases (BM). METHODS: Seventy‐eight non‐small cell lung cancer patients with BM were observed, includi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119610/ https://www.ncbi.nlm.nih.gov/pubmed/29947170 http://dx.doi.org/10.1111/1759-7714.12795 |
_version_ | 1783352105258450944 |
---|---|
author | Zhu, Ying Fu, Lei Jing, Wang Guo, Dong Kong, Li Yu, Jinming |
author_facet | Zhu, Ying Fu, Lei Jing, Wang Guo, Dong Kong, Li Yu, Jinming |
author_sort | Zhu, Ying |
collection | PubMed |
description | BACKGROUND: We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first‐line treatment for brain metastases (BM). METHODS: Seventy‐eight non‐small cell lung cancer patients with BM were observed, including 45 patients who received WBRT plus TMZ (TMZ + WBRT) and 33 patients who received WBRT alone (WBRT). The primary outcome was overall survival (OS). Secondary outcomes included progression‐free survival (PFS), objective response rate (ORR), and adverse events. RESULTS: The TMZ + WBRT arm achieved significant improvement in ORR (P = 0.0108) compared to the WBRT arm. PFS in the TMZ + WBRT arm was significantly longer than in the RT arm (6.0 vs. 3.5 months; P = 0.038). OS was not significantly different between the two arms. Although increased adverse reactions were experienced in the TMZ + WBRT arm, patients were tolerant of the side effects. Statistically significant differences in neurocognitive function and quality of life were observed between the arms at six months. CONCLUSION: Concomitant TMZ + WBRT compared to WBRT alone significantly increases ORR and median PFS in patients with BM, but no remarkable difference in median OS was found. Adding TMZ to the treatment strategy could prevent neurocognitive function and quality of life from deteriorating. Although the addition of TMZ increases the incidence of adverse effects, no significant difference was observed. Thus, TMZ is safe and effective. |
format | Online Article Text |
id | pubmed-6119610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-61196102018-09-05 Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases Zhu, Ying Fu, Lei Jing, Wang Guo, Dong Kong, Li Yu, Jinming Thorac Cancer Original Articles BACKGROUND: We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first‐line treatment for brain metastases (BM). METHODS: Seventy‐eight non‐small cell lung cancer patients with BM were observed, including 45 patients who received WBRT plus TMZ (TMZ + WBRT) and 33 patients who received WBRT alone (WBRT). The primary outcome was overall survival (OS). Secondary outcomes included progression‐free survival (PFS), objective response rate (ORR), and adverse events. RESULTS: The TMZ + WBRT arm achieved significant improvement in ORR (P = 0.0108) compared to the WBRT arm. PFS in the TMZ + WBRT arm was significantly longer than in the RT arm (6.0 vs. 3.5 months; P = 0.038). OS was not significantly different between the two arms. Although increased adverse reactions were experienced in the TMZ + WBRT arm, patients were tolerant of the side effects. Statistically significant differences in neurocognitive function and quality of life were observed between the arms at six months. CONCLUSION: Concomitant TMZ + WBRT compared to WBRT alone significantly increases ORR and median PFS in patients with BM, but no remarkable difference in median OS was found. Adding TMZ to the treatment strategy could prevent neurocognitive function and quality of life from deteriorating. Although the addition of TMZ increases the incidence of adverse effects, no significant difference was observed. Thus, TMZ is safe and effective. John Wiley & Sons Australia, Ltd 2018-06-27 2018-09 /pmc/articles/PMC6119610/ /pubmed/29947170 http://dx.doi.org/10.1111/1759-7714.12795 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Zhu, Ying Fu, Lei Jing, Wang Guo, Dong Kong, Li Yu, Jinming Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases |
title | Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases |
title_full | Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases |
title_fullStr | Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases |
title_full_unstemmed | Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases |
title_short | Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases |
title_sort | effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119610/ https://www.ncbi.nlm.nih.gov/pubmed/29947170 http://dx.doi.org/10.1111/1759-7714.12795 |
work_keys_str_mv | AT zhuying effectivenessoftemozolomidecombinedwithwholebrainradiotherapyfornonsmallcelllungcancerbrainmetastases AT fulei effectivenessoftemozolomidecombinedwithwholebrainradiotherapyfornonsmallcelllungcancerbrainmetastases AT jingwang effectivenessoftemozolomidecombinedwithwholebrainradiotherapyfornonsmallcelllungcancerbrainmetastases AT guodong effectivenessoftemozolomidecombinedwithwholebrainradiotherapyfornonsmallcelllungcancerbrainmetastases AT kongli effectivenessoftemozolomidecombinedwithwholebrainradiotherapyfornonsmallcelllungcancerbrainmetastases AT yujinming effectivenessoftemozolomidecombinedwithwholebrainradiotherapyfornonsmallcelllungcancerbrainmetastases |